133 related articles for article (PubMed ID: 22212895)
1. Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity.
Tesei A; Brigliadori G; Carloni S; Fabbri F; Ulivi P; Arienti C; Sparatore A; Del Soldato P; Pasini A; Amadori D; Silvestrini R; Zoli W
J Cell Physiol; 2012 Oct; 227(10):3389-96. PubMed ID: 22212895
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Shirsath N; Rathos M; Chaudhari U; Sivaramakrishnan H; Joshi K
Lung Cancer; 2013 Nov; 82(2):214-21. PubMed ID: 24051085
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
4. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
6. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
[TBL] [Abstract][Full Text] [Related]
8. New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity.
Perrino E; Cappelletti G; Tazzari V; Giavini E; Del Soldato P; Sparatore A
Bioorg Med Chem Lett; 2008 Mar; 18(6):1893-7. PubMed ID: 18294844
[TBL] [Abstract][Full Text] [Related]
9. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Shoji M; Ninomiya I; Makino I; Kinoshita J; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Kitagawa H; Fushida S; Harada S; Fujimura T; Ohta T
Int J Oncol; 2012 Jun; 40(6):2140-6. PubMed ID: 22469995
[TBL] [Abstract][Full Text] [Related]
11. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Groh T; Hrabeta J; Khalil MA; Doktorova H; Eckschlager T; Stiborova M
Int J Oncol; 2015 Jul; 47(1):343-52. PubMed ID: 25963435
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells.
Attoub S; Hassan AH; Vanhoecke B; Iratni R; Takahashi T; Gaben AM; Bracke M; Awad S; John A; Kamalboor HA; Al Sultan MA; Arafat K; Gespach C; Petroianu G
Eur J Pharmacol; 2011 Jan; 651(1-3):18-25. PubMed ID: 21074525
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Abaza MS; Bahman AM; Al-Attiyah RJ
Int J Mol Med; 2014 Aug; 34(2):513-32. PubMed ID: 24899129
[TBL] [Abstract][Full Text] [Related]
15. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Jasek E; Lis GJ; Jasinska M; Jurkowska H; Litwin JA
Anticancer Res; 2012 Jul; 32(7):2791-9. PubMed ID: 22753739
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
17. Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kim TH; Yoo YH; Kang DY; Suh H; Park MK; Park KJ; Kim SH
Int J Oncol; 2009 May; 34(5):1353-62. PubMed ID: 19360347
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid in the complex therapy of malignant tumors.
Hrebackova J; Hrabeta J; Eckschlager T
Curr Drug Targets; 2010 Mar; 11(3):361-79. PubMed ID: 20214599
[TBL] [Abstract][Full Text] [Related]
19. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Catalano MG; Fortunati N; Pugliese M; Poli R; Bosco O; Mastrocola R; Aragno M; Boccuzzi G
J Endocrinol; 2006 Nov; 191(2):465-72. PubMed ID: 17088416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]